Investors in It

Candy Ventures is a portfolio of global companies funded by British entrepreneur Nick Candy. We back visionary founders with global ambitions and leverage our exceptional network to powerfully accelerate businesses and ideas.To date we have funded over 25 companies across several sectors, including fintech, deep tech and augmented reality, digital media, consumer and sports, biotech, water infrastructure and natural resources.

NP Capital, headquartered in Luxembourg, is a Venture Capital firm that specializes in investments in growth and late-stage private technology companies in the US, Europe, and emerging markets.

Black Swan Equity Partners LLP is an investment advisor based in London, specializing in providing strategic advice and investment solutions. The firm focuses on advising clients on investment strategies and opportunities across various sectors. With a commitment to delivering tailored financial solutions, Black Swan Equity Partners works closely with investors and businesses to optimize their investment portfolios and achieve their financial goals. The firm's expertise lies in offering personalized advisory services that cater to the unique needs and objectives of its clients, aiming to build long-term value and sustainable growth.

The ALS Investment Fund supports and finances biotech companies that develop drugs and diagnostics for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. The ALS Investment Fund was initiated by Dutch ALS patients and is advised by a top-tier European VC firm, Life Sciences Partners. The ALS Investment Fund invests globally, but focuses on Europe and the US. The fund brings depth of disease-specific knowledge and a deep network in the space.

Humanity will always depend on medicines. Continuous innovation in the biotech sector is a given. Bringing better medicines to the market all the time. The Aescap Life Sciences and Aescap Genetics funds invest in highly innovative publicly traded biotech/life sciences companies. These companies are developing tomorrow’s medicines. Investing in Aescap funds offers the possibility to achieve excellent returns over the medium term, without taking large risks. Both funds have a focused portfolio, based on deep fundamental analyses and a strict buy and sell discipline. The Aescap funds act under the Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR) and operate under a AIFM license.

Foresight Group, we are a leading independent investor headquartered in the United Kingdom, specializing in infrastructure, private equity, and environmental sectors. Our focus on sustainability drives our investment strategy as we manage funds for institutional and private investors globally, aiming to deliver attractive, risk-adjusted returns. With expertise spanning renewable energy, waste management, sustainable infrastructure, and technology-driven growth businesses, we actively seek opportunities to support companies in scaling and realizing their full potential. Integrating environmental, social, and governance (ESG) considerations into our investment decisions, we strive to create positive impacts and sustainable outcomes across our diverse portfolio. With a strong track record and a commitment to innovation, we continue to drive economic growth while contributing to environmental sustainability and societal well-being worldwide.

Founded in 1984 by Queen's University Belfast, QUBIS Ltd is dedicated to commercializing the university's research and development activities through the creation of spin-out businesses. We play a crucial role in this process by acquiring equity in new spin-out ventures, leveraging investments in cash and/or Intellectual Property. Our primary mission is to transition innovative R&D from the laboratory to the commercial marketplace. At QUBIS Ltd, we proactively identify and evaluate commercially viable research and resources within Queen's University. We collaborate closely with skilled management teams and partners who possess the necessary market expertise to drive these ventures forward. Our approach is market-driven, focusing exclusively on ventures with strong market validation and demand. We recognize the importance of partnering with private or trade investors who can contribute not only capital but also valuable market access. This collaboration allows us to effectively navigate market challenges and leverage established distribution systems or market presence. By bridging academia and industry, we are committed to facilitating the transformation of cutting-edge research into impactful innovations that benefit society and drive economic growth.

5square is an independent investment company dedicated to backing inspirational entrepreneurs and their ventures. Our mission is to empower entrepreneurs to reach their full potential by providing strategic capital and hands-on support. We are committed to fostering healthy and sustainable growth in the companies we invest in, embodying what we call Committed Capital. Since our establishment in 2004, 5square has been the preferred investor for ambitious entrepreneurs seeking more than just financial backing. We bring a wealth of experience and a proactive approach to every partnership, ensuring our portfolio companies thrive and succeed in competitive markets. Our track record speaks to our commitment to long-term value creation and our role as trusted partners in entrepreneurial journeys.

TRGC is committed to a hands-on approach with its portfolio companies, aiming to add value from day one. With over 15 years of industry experience, TRGC leverages its expertise to support promising founders who demonstrate visionary ideas and strong execution capabilities. The firm prioritizes active involvement and strategic guidance, working closely with entrepreneurs to navigate challenges, accelerate growth, and achieve impactful outcomes. TRGC's dedication to backing innovative ventures reflects its commitment to fostering long-term success and driving positive change within the industries it invests in. For more information, you can visit their website: TRGC

NPIF – Mercia Equity Finance, managed by Mercia Asset Management, is a venture capital fund dedicated to supporting innovative businesses across various growth stages. We operate as part of the Northern Powerhouse Investment Fund (NPIF), backed by the European Regional Development Fund (ERDF) and the UK government. Our focus is on early-stage and growth-stage companies primarily located in the North of England. We provide equity finance, ranging from seed funding for startups to growth capital for established firms, aiming to fuel their expansion, product development, and market reach. At NPIF – Mercia Equity Finance, our expertise spans sectors such as technology, life sciences, advanced manufacturing, and digital industries. We leverage our sector knowledge and extensive network to identify promising investment opportunities aligned with strategic growth sectors in the North of England. By partnering with regional stakeholders, including local authorities and business support organizations, we maximize our impact on the local economy. Our collaborative approach aims to foster innovation, create jobs, and enhance economic competitiveness across the Northern Powerhouse region. Overall, we play a vital role in supporting entrepreneurs and businesses on their growth journey, contributing to economic resilience and regional development.

SET Ventures was founded in 2007 with the sole purpose of backing European innovation in clean energy. At that time, we were one of the only investors in this space, but almost 20 years later, we’re proud to not only have raised our fourth fund but to have helped turn the energy transition from an afterthought into a global movement.

BioGeneration Ventures (BGV) is a venture capital company focused on early-stage European biotech, medtech, and diagnostics companies. With a strong track record of significant financial returns, BGV invests in healthcare innovations and builds world-class teams. The company manages over €100 million, targeting areas where scientific innovation, unmet medical needs, and the potential for significant proof of concept converge. BGV collaborates with founding teams to mature science and build companies, using its expertise to guide progress into clinical trials, leading to successful drug development and value realization for its investors.